Press coverage about TESARO (NASDAQ:TSRO) has been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TESARO earned a news sentiment score of 0.04 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.0333851657094 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
TESARO (NASDAQ:TSRO) opened at $64.38 on Friday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 4.39 and a current ratio of 4.74. The company has a market capitalization of $3,524.83, a P/E ratio of -7.01 and a beta of 1.40. TESARO has a twelve month low of $52.20 and a twelve month high of $168.92.
TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($3.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.39) by ($0.96). The firm had revenue of $48.02 million during the quarter, compared to analysts’ expectations of $51.78 million. TESARO had a negative return on equity of 126.44% and a negative net margin of 222.15%. research analysts expect that TESARO will post -9.54 EPS for the current year.
Several analysts have weighed in on the company. BidaskClub upgraded TESARO from a “sell” rating to a “hold” rating in a research report on Tuesday. Morgan Stanley lowered their price objective on TESARO from $156.00 to $146.00 and set an “overweight” rating for the company in a research report on Thursday, March 1st. ValuEngine upgraded TESARO from a “sell” rating to a “hold” rating in a research report on Friday, March 2nd. Credit Suisse Group reiterated an “in-line” rating and issued a $141.00 price objective (down previously from $150.00) on shares of TESARO in a research report on Wednesday, February 28th. Finally, Wells Fargo & Co reiterated an “outperform” rating and issued a $122.00 price objective (down previously from $224.00) on shares of TESARO in a research report on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. TESARO presently has an average rating of “Buy” and an average price target of $133.39.
In other news, CEO Leon O. Moulder, Jr. purchased 5,000 shares of TESARO stock in a transaction that occurred on Friday, March 2nd. The shares were bought at an average cost of $56.93 per share, with a total value of $284,650.00. Following the completion of the purchase, the chief executive officer now directly owns 1,018,828 shares in the company, valued at $58,001,878.04. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David M. Mott purchased 68,302 shares of TESARO stock in a transaction that occurred on Friday, March 2nd. The stock was purchased at an average cost of $55.56 per share, for a total transaction of $3,794,859.12. Following the completion of the purchase, the director now owns 12,825 shares of the company’s stock, valued at $712,557. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 334,913 shares of company stock worth $19,083,294 and sold 13,042 shares worth $760,526. 40.50% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “TESARO (TSRO) Receiving Somewhat Positive News Coverage, Analysis Finds” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/16/tesaro-tsro-receiving-somewhat-positive-news-coverage-analysis-finds.html.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.